Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Semaglutide wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Pramlintide and Semaglutide have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-titrated. Subcutaneous injection immediately before major meals. Type 1 diabetes: typically start 15 µg and titrate to 30-60 µg per meal. Type 2 diabetes (on mealtime insulin): typically start 60 µg and titrate to 120 µg per meal. Reduce mealtime insulin (often by ~50%) when starting. DO NOT self-dose.
with-meals
Subcutaneous pre-meal injection (Symlin / SymlinPen)
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
Weeks to 6-12 months
Per meal / weeks
Months
Especially first weeks
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
Diabet Med (2004) · Rct · n=651
Double-blind, placebo-controlled, parallel-group phase-3 RCT in 651 patients with type 1 diabetes, mealtime pramlintide vs placebo added to insulin for 52 weeks
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Diabetes Care (2002) · Rct · n=480
52-week double-blind, placebo-controlled RCT in 480 patients with type 1 diabetes, 30 µg pramlintide QID vs placebo added to insulin, plus a 1-year open-label extension
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Diabetes Care (2003) · Rct · n=656
52-week double-blind, placebo-controlled, parallel-group phase-3 RCT in 656 insulin-treated patients with type 2 diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Semaglutide has a higher evidence score (8.5/10 vs 5/10) and wins in 1 of 3 categories.
No known interactions between Pramlintide and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.